FIELD: biotechnology.
SUBSTANCE: disclosed is an antibody which specifically binds to Gremlin-1. Also disclosed is an isolated polynucleotide coding an anti-gremlin-1 antibody, comprising said polynucleotide expression vector and a host cell. Also disclosed is a method of producing anti-gremlin-1 antibody, involving culturing said host cell. Invention also relates to use of said antibody for treating or preventing pulmonary arterial hypertension.
EFFECT: invention provides specific binding with high affinity and inhibiting activity of the antibody with respect to Gremlin-1.
16 cl, 16 dwg, 6 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| GREMLIN-1 INHIBITOR FOR THE TREATMENT OF BONE FRACTURE OR BONE DEFECT | 2019 |
|
RU2790992C2 |
| PREDICTION OF RISK OF DEVELOPMENT OF UNDESIRED REACTION RELATED TO ADMINISTRATION OF ANTIBODY TO ALK2 AND CAPABILITY OF RESPONDING TO TREATMENT WITH ANTIBODY TO ALK2 | 2019 |
|
RU2783762C2 |
| CONNECTIVE TISSUE GROWTH FACTOR ANTIBODY AND USE THEREOF | 2020 |
|
RU2819228C2 |
| ANTIBODIES TO MYOSTATIN, POLYPEPTIDES CONTAINING FC-REGION VARIANTS, AND THEIR APPLICATION METHODS | 2016 |
|
RU2789884C2 |
| FUSED PROTEIN CONSTRUCTS FOR COMPLEMENT-RELATED DISEASE | 2019 |
|
RU2824402C2 |
| BISPECIFIC ANTIBODY AGAINST RABIES VIRUS AND ITS APPLICATION | 2019 |
|
RU2764740C1 |
| ANTIBODIES TO MYOSTATIN AND THEIR APPLICATION METHODS | 2017 |
|
RU2778945C2 |
| IMMUNOCYTOKINES AND THEIR USE | 2021 |
|
RU2818371C1 |
| ANTIBODY CAPABLE OF BINDING TO THYMIC STROMAL LYMPHOPOIETIN, AND USE THEREOF | 2020 |
|
RU2825304C2 |
| ANTIBODIES TO MYOSTATIN, POLYPEPTIDES CONTAINING FC REGION VARIANTS AND METHODS OF THEIR USE | 2015 |
|
RU2799522C2 |
